EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Imidazolinium-Based NHC–Metal Complexes Overcome Both Cancer Multidrug Resistance and Cisplatin Resistance In Vitro

Márton Szlávik, Ines Lidia Haffaressas, Réka Mandel, Fanni Fekecs, Ágota Apáti iD, Attila Paczal, András Kotschy iD, Gergely Szakács iD, Szilárd Tóth iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Márton Szlávik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servier Research Institute of Medicinal Chemistry, Záhony Utca 7, H-1031 Budapest, Hungary. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Coordination Complexes, Cisplatin, Drug Resistance, Multiple. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Laboratories Programme, National Laboratory for Drug Research and Development (PharmaLab), National Research, Development and Innovation Fund, FWF Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the synthesis and biological characterization of N-heterocyclic carbene (NHC) complexes with gold(I), silver(I), copper(I), and palladium(II) metal centers, and 3-(2,6-diisopropyl-phenyl) imidazolinium- and imidazolium-based ligands, including their biscarbene complexes, along with metal complexes of 4-(S)-tert-butyl-imidazolinium-derived carbenes carrying various substituents in position 1. Compared to the imidazolium complexes, the corresponding imidazolinium complexes displayed superior cytotoxicity against the Mes-Sa uterine sarcoma cell line, while the biscarbene complexes exhibited greatly enhanced cytotoxicity with nanomolar activity. The ABCB1-overexpressing multidrug-resistant sublines of Mes-Sa demonstrated only marginal resistance to monocarbene imidazolinium complexes lacking a 4-(S)-tert-butyl group, whereas significant resistance was observed for all other complexes, with its extent further influenced by the nature of the metal center. Probing a subset of the complexes confirmed their strong cytotoxicity against the CST murine breast cancer cell line and its cisplatin-resistant variant, with little or no cross-resistance observed. Within a defined subset, compounds triggered apoptosis, and intracellular ROS production was consistently induced by the copper complexes. Collectively, these results indicate that imidazolinium-based metal NHCs are promising anticancer drug candidates, with copper and silver centers standing out for their potent cytotoxicity and evasion of both ABCB1-mediated and cisplatin resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmCoordination ComplexesCisplatinDrug Resistance, MultipleAntineoplastic AgentsImidazolesHeterocyclic CompoundsMethaneCell Line, TumorHumansAnimalsMiceFemale

Stichwörter der Autor:innen

ABCB1N-heterocyclic carbenecisplatin resistancemultidrug resistance

Substanzen

Coordination ComplexesCisplatinAntineoplastic AgentsImidazolescarbeneHeterocyclic CompoundsMethane

Autor:innen und Institutionen

  • Servier Research Institute of Medicinal Chemistry, Záhony Utca 7, H-1031 Budapest, Hungary.
  • Hevesy György PhD School of Chemistry, Eötvös Loránd University, Pázmány Péter Sétány 1/A, H-1117 Budapest, Hungary.
  • Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Magyar Tudósok Körútja 2, H-1117 Budapest, Hungary.
  • Doctoral School of Biology, Institute of Biology, Eötvös Loránd University, Pázmány Péter Sétány 1/C, H-1117 Budapest, Hungary.
  • Center for Cancer Research, Medical University of Vienna, Spitalgasse 23, A-1090 Vienna, Austria.
  • National Laboratory for Drug Research and Development, H-1117 Budapest, Hungary.

ORCID-Profile: Ágota Apáti, András Kotschy, Gergely Szakács, Szilárd Tóth

Förderung

  • National Laboratories Programme, National Laboratory for Drug Research and Development (PharmaLab)
  • National Research, Development and Innovation Fund
  • FWF Austrian Science Fund
  • Austrian Science Fund

Zitieren

APA

Szlávik, M., Haffaressas, I. L., Mandel, R., Fekecs, F., Apáti, Á., Paczal, A., Kotschy, A., Szakács, G., & Tóth, S. (2025). Imidazolinium-Based NHC–Metal Complexes Overcome Both Cancer Multidrug Resistance and Cisplatin Resistance In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311382

Vancouver

Szlávik M, Haffaressas IL, Mandel R, Fekecs F, Apáti Á, Paczal A, et al. Imidazolinium-Based NHC–Metal Complexes Overcome Both Cancer Multidrug Resistance and Cisplatin Resistance In Vitro. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311382

BibTeX
@article{Szlvik2025,
  author = {Szlávik, Márton and Haffaressas, Ines Lidia and Mandel, Réka and Fekecs, Fanni and Apáti, Ágota and Paczal, Attila and Kotschy, András and Szakács, Gergely and Tóth, Szilárd},
  title = {Imidazolinium-Based NHC–Metal Complexes Overcome Both Cancer Multidrug Resistance and Cisplatin Resistance In Vitro},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311382}
}
Kostenlos starten →